Keywords: genset, shares, up, preclinical, testing, obesity, drug

Genset shares up 17.5% on preclinical testing of obesity drug Famoxin

Article | 07 February 2001

Print This

Trading in the stock of the French biotechnology company Genset wasbriefly suspended because of a flood of buyers this past ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in